Trials / Completed
CompletedNCT02022540
Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD
A Phase I Open-Label, Multi-Center Trial With Randomization to Dose to Evaluate the Safety and Tolerability of Topical Ocular PAN-90806 in Patients With Neovascular Age-Related Macular Degeneration (AMD)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- PanOptica, Inc. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to assess the safety and tolerability of topical ocular PAN-90806 in patients with active, subfoveal choroidal neovascularization associated with neovascular Age-Related Macular Degeneration (AMD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PAN-90806 Ophthalmic Solution | |
| DRUG | Lucentis |
Timeline
- Start date
- 2014-02-01
- Primary completion
- 2016-03-01
- Completion
- 2016-05-01
- First posted
- 2013-12-27
- Last updated
- 2016-09-28
Locations
22 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02022540. Inclusion in this directory is not an endorsement.